> ## Content Index
> Fetch the complete content index at: https://chinapharmadesk.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# BrightGene reports a Phase 3 glucose-control edge over semaglutide 1 mg
- URL: https://chinapharmadesk.com/brightgene-bgm0504-diabetes-phase3-semaglutide-1mg-2026-11-12/
- Published: 2026-11-12T13:28:56.000Z
- Updated: 2026-11-12T13:28:56.000Z
- Description: BrightGene reports a 32-week HbA1c advantage for BGM0504 10 mg over semaglutide 1 mg. The diabetes program still needs a filing and approval.
- Author: LinYi
- Tags: Desk brief, Pipeline

BrightGene has reported that the 10 mg dose of its experimental GLP-1/GIP drug BGM0504 lowered blood sugar more than once-weekly semaglutide 1 mg in a Chinese Phase 3 trial. The result adds an active-comparator readout to its diabetes program; it is not a marketing approval.

In a [filing dated November 12](https://static.cninfo.com.cn/finalpage/2026-11-12/1225667369.PDF?ref=chinapharmadesk.com), the company reported 553 participants whose diabetes was inadequately controlled on metformin, with or without a sulfonylurea. At week 32, HbA1c—a measure of longer-term blood glucose—fell by 2.41 percentage points with BGM0504 10 mg, versus 1.95 points with semaglutide. BrightGene said the difference was statistically significant, using its treatment-regimen analysis.

BGM0504 5 mg met non-inferiority at that time point. Treating both doses as equally superior would overstate the finding.

The [trial registration](https://clinicaltrials.gov/study/NCT06716216?ref=chinapharmadesk.com) identifies the 1 mg weekly comparator and a 32-week HbA1c primary endpoint. BrightGene describes blinding between its experimental doses, with an open-label active comparator. These particulars matter when reading broader claims about beating semaglutide: the comparison concerns this regimen, population and endpoint, not every dose, indication or outcome.

The company described most gastrointestinal reactions as mild to moderate. It reported no severe hypoglycemia and a 0.54% withdrawal rate due to study-drug-related adverse events in the experimental arms over 52 weeks. Those topline descriptions do not replace a complete safety dataset.

BrightGene says its obesity application remains under Chinese review and that it plans a diabetes filing. Approval, pricing and reimbursement decisions remain ahead.

*AI-assisted reporting based on the linked disclosures. Industry information only—not medical or investment advice.*